Exelixis Inc's Customers Performance

Name: Exelixis Inc Customers by Division and Industry - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use

EXEL

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.


EXEL's Source of Revenues		During the corresponding time, Exelixis Inc recorded a revenue increase by 9.97 % year on year, sequentially revenue grew by 2.03 %. While revenue at the Exelixis Inc 's corporate clients • List of EXEL Customers

for the same period Exelixis Inc recorded revenue increase by 9.97 % year on year, sequentially revenue grew by 2.03 %.

• List of EXEL Customers

Exelixis Inc's Business Units


Reportable Segment	100 %	of total Revenue
Gross product revenues	130.21 %	of total Revenue
Discounts and allowances	-39.35 %	of total Revenue
Net product revenues	90.86 %	of total Revenue
License revenues	9.32 %	of total Revenue
Collaboration services revenues	-0.18 %	of total Revenue
Collaboration revenues	9.14 %	of total Revenue
U S	91.44 %	of total Revenue
Europe	6.48 %	of total Revenue
Japan	2.08 %	of total Revenue
CABOMETYX	90.5 %	of total Revenue
COMETRIQ	0.36 %	of total Revenue
Ipsen And Takeda Collaborations	9.81 %	of total Revenue
Collaborative Arrangement with Ipsen	6.48 %	of total Revenue
License revenues Collaborative Arrangement with Ipsen	7.13 %	of total Revenue
Collaboration services revenues Collaborative Arrangement with Ipsen	-0.65 %	of total Revenue
Collaborative Arrangement with Takeda	1.72 %	of total Revenue
License revenues Collaborative Arrangement with Takeda	1.25 %	of total Revenue
Collaboration services revenues Collaborative Arrangement with Takeda	0.47 %	of total Revenue

Select the Relationship:

Customers ▼

Select the Category:

Comparison ▼

Customers ▼

Basic Report▼

Exelixis Inc's Comment on Sales, Marketing and Customers

News about Exelixis Inc Contracts

Exelixis Announces U.S. Food and Drug Administration (FDA) Accepted the Supplemental New Drug Application for Cabozan...

Cabozantinib Receives FDA Nod for Advanced Neuroendocrine Tumors: What This Means for Exelixis Future Exelixis, Inc. has been at the forefront of oncological innovations, and their recent breakthrough is no less impressive. The U.S. Food and Drug Administration’s (FDA) acceptance of their supplemental New Drug Application (sNDA) for cabozantinib (marketed as CABOMETYX) marks a significant leap forward in the treatment of specific advanced neuroendocrine tumors. This article delves into the nuanced impacts of this regulatory milestone for Exelixis and how it could redefine therapeutic approaches for patients with challenging cancer types. Understanding the Supplemental New Drug ApplicationThe FDA has acce...

EXEL's Stock Performance relative to it's Customers

EXEL's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Exelixis Inc	15,036.86	2,375.49	1,836.62	1,147
SUBTOTAL	0.00	0.00	0.00	-

Sources: Exelixis Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Exelixis Inc’s corporate clients.
For your research, we’ve provided 9 tables on Exelixis Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.